Guggenheim Lowers Illumina's Price Target to $114, Maintains 'Buy' Rating
May 12, 2025 17:37
CST Updated
17:37
Illumina
Diagnostic Product Developer
Gelonghui May 12 | Guggenheim: Downgraded Illumina's target price from $122 to $114, maintained "Buy" rating. (Gelonghui)